Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRd vs DRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT06679101Phase 3Recruiting
- Sponsor
- GSK
- Start
- Dec 2024
- Primary completion
- Apr 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 24
01
Overview
A Phase 3 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Dec 2024; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06679101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679101.